Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the
gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or …

Genotyping tumor tissue in search of somatic genetic alterations for actionable information
has become routine practice in clinical oncology. Although these sequence alterations are …

Background Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and
other diseases. Currently, more than 25 oncology drugs that target kinases have been …

Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …

Stem cell factor (SCF) is a dimeric molecule that exerts its biological functions by binding to
and activating the receptor tyrosine kinase c-Kit. Activation of c-Kit leads to its …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …